In parts of war-torn Ethiopia, bullet casings are easy to find. Raven and Lily help Ethiopian artisans turn the raw material from those deadly artifacts toward more pleasant uses.
In Ethiopia, being female and HIV-positive can be a double whammy: Many women are ostracized from their communities as well as getting sick. Raven and Lily is trying to help HIV-positive women by giving them jobs making jewelry from bullet casings and coins.
![]() |
This is how it works: The company works with three different village communities in Ethiopia. Farmers gather artillery shells from former war conflicts as they plow their fields. They then sell the bullet casings to the villagers skilled in the traditional techniques of bead making. These farmers and villagers live in very remote parts of Ethiopia, so the beads are always brought to the main cities to be sold.
Raven and Lily bypasses the city markets and works directly with the bead makers to ensure they are the ones getting the most money for their craftsmanship. “I love the imperfect beauty of each hand-made bead,” says co-founder Kirsten Dickerson. “It’s really amazing to me that what was once meant for harm now brings hope and life to the HIV-positive women in our partnership.”
The company also works in India and is launching a new product line in Cambodia. Dickerson says that the process of partnering takes some time. “When we decide to partner with a group of women who have learned a design skill, one of the first things we do is assess what types of locally made materials the women can utilize,” she says. “We really try as much as possible to ensure that not only the women in our direct trade partnership are receiving fair wages, but also the communities that product the base materials.”
Dickerson says that the company goes beyond fair wages and works with the communities to ensure that the women and their families have access to health care, education, savings accounts, and a community that doesn’t shun them. “We are able to witness firsthand the transformation that is happening in the lives of these women and their families,” she says.
Today Bing is announcing a revamp of its front end, to make its search results more useful for users. But what's much more interesting is what's happening on the back end, underneath the hood, as Microsoft re-architects how the data used for search results is collected, stored, and repurposed.
Is that all?
When Google was created over a decade ago, the Internet was basically a set of pages. Google's innovation was to develop a system that would locate what pages existed on the Internet and then determine how relevant each was to specific keywords. For that, it created an architecture of "indexing” and "ranking” pages. Thus was Google's famous search algorithm born.
Bing, however, believes the approach of indexing and ranking pages is no longer sufficient. Helping people find answers shouldn't just be about pointing you to documents elsewhere and making you do the work of clicking over and figuring out if they have the information you need.
Instead, Bing thinks search should be more about helping you get things done right in the search results themselves. In cases where they can reasonably predict what you're trying to accomplish, search should provide widgets in the results that let you get the job done. For example, if you enter the keywords "The Avengers Chicago,” it's reasonable to assume you're looking for movie show times. Why not post a list of show times right in the results, instead of making you click over to a page of moving listings?
But to provide that level of service, a simple list of pages on the Internet isn't enough. You need a whole different kind of database on the back end. And that's what Bing is working on creating.
"Our goal is to model every object on the planet,” Weitz says. So far the company has compiled a database of 300 million objects, from computer mice to buildings. As Bing's bots crawl the web, they identify pages that have information about those objects. And then they use that information to develop an understanding of what kinds of things people might want to do with that object.The goal is to use the understandings they're gathering, and the data they're collecting, to identify and build the kinds of apps for search results that will help you accomplish tasks without making you click over to a second page.
"We're literally no longer indexing text,” Weitz says. "We're trying to associate data that exists on the web in all forms with the physical object that spawned it in the first place.”
"It's so important for us to understand the object layer of the web because that tells us what actions people can perform on it,” Weitz says. "So suddenly, you go from asking a question like, ‘Where do I buy a mouse?'… to knowing that there are different applications that can fulfill that request.”
Google, of course, is also working on this problem. Back in March, a Google executive told the Wall Street Journal the company had compiled a similar, massive encyclopedia of "entities,” or people, places, and things.
And they're not the only ones. Facebook reportedly is also compiling a database of things that people talk about and share on the social network. And Apple's Siri is also working on the problem, so it can understand the questions users ask it.
All of which is to say that a massive game change is waiting in the wings in the search business. And it won't just affect the search competitors as they race to develop the most powerful models. It will also affect the SEO industry that has spent the past decade trying to master page rank. The more the search engines create apps to help people accomplish tasks right in the results, the fewer referrals they'll be making to outside pages.
• Onetime "King of Biotech" Breaks Law Again More...
• Eli Lilly and Company (LLY) and Abbott Laboratories (ABT) Win Big in Sales Rep Overtime Case More...
• Watson Pharmaceuticals, Inc. (WPI) Confirms Lialda® Patent Challenge More...
• 400 Jobs to Go as Patheon Inc. (PTI.TO) Winds Down Swindon Operation More...
• GE Healthcare Life Sciences Completes Acquisition of Xcellerex, Inc.More...
• Spectrum Pharmaceuticals, Inc. (SPPI) and Allos Therapeutics, Inc. (ALTH) Announce Extension of Previously Announced Tender Offer for Shares of Allos Therapeutics More...
• Aeras Global TB Vaccine Foundation and Infectious Disease Research Institute (IDRI) Sign Agreement to Jointly Develop Novel Tuberculosis Vaccine More...
• SK Bio-Pharmaceuticals Enters into a Licensing Agreement With Hanmi Pharmaceutical, Co., Ltd More...
• Genetic Technologies Limited (GTG.AX) Executes Settlement and License Agreement With GeneSeek Inc. More...
• TAP Biosystems Collaborates With OU to Develop Biomimetic 3D CNS Models Novel Approach Could Contribute to Reducing Number of Pre-Clinical Animal Studies More...
• Dr. Philippe Calais Appointed Chief Executive Officer of ANTISENSE PHARMA GmbH More...
• AMAG Pharmaceuticals, Inc. (AMAG) Appoints William Heiden as President and Chief Executive Officer More...
• LaserGen, Inc. Names Dr. Mimi Healy as CEO More...
• RXi Pharmaceuticals (RXII) Appoints Industry Veteran Dr. Geert Cauwenbergh as President and Chief Executive Officer More...
• Achillion Pharmaceuticals, Inc. Reports First Quarter 2012 Financial Results More...
• A.P. Pharma, Inc. (APPA) Announces First Quarter 2012 Financial Results and Recent Corporate Progress More...
• Auxilium Pharmaceuticals (AUXL) Announces First Quarter 2012 Financial Results More...
• Bioniche Life Sciences Inc. (BNC) Reports Q3, Fiscal 2012 Results More...
• Biodel Inc. (BIOD) Reports Second Quarter Fiscal Year 2012 Financial Results More...
• Pfizer Inc. (PFE)'s RA Drug Wins FDA Panel Support More...
• Johnson & Johnson (JNJ) Seeks Further FDA Thrombosis OK for Xarelto More...
• Janssen Research & Development Submits Supplemental New Drug Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce the Risk of Stent Thrombosis in Patients with Acute Coronary Syndrome More...
• Biogen Idec, Inc. (Massachusetts) (BIIB) Release: US and EU Regulatory Authorities Accept Oral BG-12 Marketing Applications for Review More...
• Lethal Injection Drug from Naari AG Held by Nebraska is Recalled More...
• GlaxoSmithKline (GSK): We Complied With Indian Rules for Drug Approval More...
• Aastrom Biosciences, Inc. (ASTM) Announces First Patient Enrolled in REVIVE Phase 3 Clinical Trial of Ixmyelocel-T More...
• FDA and Repros Therapeutics Inc. (RPRX) Reach Agreement for Androxal® Registration Program More...
• Clal Biotechnology Industries Release: Andromeda Announces That Further Data Analyses Support Primary Endpoint in Andromeda Biotech's Phase III Clinical Study More...
• Celgene Corporation (CELG) Release: The New England Journal of Medicine Reports on Three Phase III REVLIMID® (lenalidomide) Trials in Patients with Newly Diagnosed Multiple Myeloma More...
• Testosterone-Fuelled Infantile Males Might Be a Product of Mom's Behaviour,University Of Montreal Study More...
• Kids Who Sleep With Parents Tend to Be "Slimmer," Copenhagen University Hospital Study More...
• Stem Cell Shield "Could Protect Cancer Patients," Cancer Research UK Cambridge Research Institute Study More...
• Why Do People Choke When the Stakes Are High?, California Institute of Technology Study More...
• Nitto Denko Corporation (XETRA: ND5.DE) Obtains US Patent for Antifibrotic Therapies with Molecular Targeting DDS Technology More...
• TrovaGene, Inc., Announces Issuance of European Patent for Detection of Pathogenic Infections More...
• Lipitor Clone Lifts Ranbaxy Laboratories (RANBAXY.BO) While Pfizer Inc. (PFE) Bids Drug Goodbye More...
• Roche (RHHBY) Wins UK National Institute for Clinical Excellence (NICE) Backing for Tarceva in Advanced Lung Cancer More...
• Johnson & Johnson (JNJ) Opens Doxil Rationing Program to New Patients More...
• Teijin Pharma's Febuxostat (FEBURIC) Launches in Taiwan - Novel Drug for Treatment of Hyperuricemia With Gout More...
• TherapeuticsMD, Inc. Launches vitaMedMD RediChew RX, the First Daily Chewable Prescription Prenatal Vitamin with Quatrefolic More...
• Eli Lilly and Company (LLY) and Abbott Laboratories (ABT) Win Big in Sales Rep Overtime Case More...
• Watson Pharmaceuticals, Inc. (WPI) Confirms Lialda® Patent Challenge More...
• 400 Jobs to Go as Patheon Inc. (PTI.TO) Winds Down Swindon Operation More...
• GE Healthcare Life Sciences Completes Acquisition of Xcellerex, Inc.More...
• Spectrum Pharmaceuticals, Inc. (SPPI) and Allos Therapeutics, Inc. (ALTH) Announce Extension of Previously Announced Tender Offer for Shares of Allos Therapeutics More...
• Aeras Global TB Vaccine Foundation and Infectious Disease Research Institute (IDRI) Sign Agreement to Jointly Develop Novel Tuberculosis Vaccine More...
• SK Bio-Pharmaceuticals Enters into a Licensing Agreement With Hanmi Pharmaceutical, Co., Ltd More...
• Genetic Technologies Limited (GTG.AX) Executes Settlement and License Agreement With GeneSeek Inc. More...
• TAP Biosystems Collaborates With OU to Develop Biomimetic 3D CNS Models Novel Approach Could Contribute to Reducing Number of Pre-Clinical Animal Studies More...
• Dr. Philippe Calais Appointed Chief Executive Officer of ANTISENSE PHARMA GmbH More...
• AMAG Pharmaceuticals, Inc. (AMAG) Appoints William Heiden as President and Chief Executive Officer More...
• LaserGen, Inc. Names Dr. Mimi Healy as CEO More...
• RXi Pharmaceuticals (RXII) Appoints Industry Veteran Dr. Geert Cauwenbergh as President and Chief Executive Officer More...
• Achillion Pharmaceuticals, Inc. Reports First Quarter 2012 Financial Results More...
• A.P. Pharma, Inc. (APPA) Announces First Quarter 2012 Financial Results and Recent Corporate Progress More...
• Auxilium Pharmaceuticals (AUXL) Announces First Quarter 2012 Financial Results More...
• Bioniche Life Sciences Inc. (BNC) Reports Q3, Fiscal 2012 Results More...
• Biodel Inc. (BIOD) Reports Second Quarter Fiscal Year 2012 Financial Results More...
• Pfizer Inc. (PFE)'s RA Drug Wins FDA Panel Support More...
• Johnson & Johnson (JNJ) Seeks Further FDA Thrombosis OK for Xarelto More...
• Janssen Research & Development Submits Supplemental New Drug Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce the Risk of Stent Thrombosis in Patients with Acute Coronary Syndrome More...
• Biogen Idec, Inc. (Massachusetts) (BIIB) Release: US and EU Regulatory Authorities Accept Oral BG-12 Marketing Applications for Review More...
• Lethal Injection Drug from Naari AG Held by Nebraska is Recalled More...
• GlaxoSmithKline (GSK): We Complied With Indian Rules for Drug Approval More...
• Aastrom Biosciences, Inc. (ASTM) Announces First Patient Enrolled in REVIVE Phase 3 Clinical Trial of Ixmyelocel-T More...
• FDA and Repros Therapeutics Inc. (RPRX) Reach Agreement for Androxal® Registration Program More...
• Clal Biotechnology Industries Release: Andromeda Announces That Further Data Analyses Support Primary Endpoint in Andromeda Biotech's Phase III Clinical Study More...
• Celgene Corporation (CELG) Release: The New England Journal of Medicine Reports on Three Phase III REVLIMID® (lenalidomide) Trials in Patients with Newly Diagnosed Multiple Myeloma More...
• Testosterone-Fuelled Infantile Males Might Be a Product of Mom's Behaviour,University Of Montreal Study More...
• Kids Who Sleep With Parents Tend to Be "Slimmer," Copenhagen University Hospital Study More...
• Stem Cell Shield "Could Protect Cancer Patients," Cancer Research UK Cambridge Research Institute Study More...
• Why Do People Choke When the Stakes Are High?, California Institute of Technology Study More...
• Genes and Vascular Risk Modify Effects of Aging on Brain and Cognition,Wayne State University Study More...
• Quick-Med Technologies (QMDT) to Receive an Eighth NIMBUS(R) Patent More...
• Quick-Med Technologies (QMDT) to Receive an Eighth NIMBUS(R) Patent More...
• Nitto Denko Corporation (XETRA: ND5.DE) Obtains US Patent for Antifibrotic Therapies with Molecular Targeting DDS Technology More...
• TrovaGene, Inc., Announces Issuance of European Patent for Detection of Pathogenic Infections More...
• Lipitor Clone Lifts Ranbaxy Laboratories (RANBAXY.BO) While Pfizer Inc. (PFE) Bids Drug Goodbye More...
• Roche (RHHBY) Wins UK National Institute for Clinical Excellence (NICE) Backing for Tarceva in Advanced Lung Cancer More...
• Johnson & Johnson (JNJ) Opens Doxil Rationing Program to New Patients More...
• Teijin Pharma's Febuxostat (FEBURIC) Launches in Taiwan - Novel Drug for Treatment of Hyperuricemia With Gout More...
• TherapeuticsMD, Inc. Launches vitaMedMD RediChew RX, the First Daily Chewable Prescription Prenatal Vitamin with Quatrefolic More...
Update: Yesterday's open positions on short side were covered at Nifty 4910.
Yesterday, Nifty had tried to rally but couldn't sustain at 5050 levels and give up some gains. We recommended to short Nifty at 5050 levels and book partial profit at 4960 levels. See here.
In asia, China was weighing on sentiment, as Consumer Inflation is higher than expected. Asia trading in red too.
Yesterday, Nifty had tried to rally but couldn't sustain at 5050 levels and give up some gains. We recommended to short Nifty at 5050 levels and book partial profit at 4960 levels. See here.
US markets closed mixed as Cisco's earnings weigh down on Nasdaq to close in a negative territory. Economic data from US was encouraging and Banking Sector to push stocks higher. Dow Jones and S&P closed in a positive territory. Meanwhile European headlines were calming investor's nerves as Greece might work out a coalition government formation and avoid Euro exit by assuring the bail out terms. Europe closed positive. The headlines from Europe will dominate friday's trading session too.
![]() |
| Nifty Trading Tips |
Tips & Outlook Today for Nifty
Our View is to short sell Nifty around 5000 levels. Yesterday's open short position were covered if Nifty drift lower. Nifty will see sub 4900 levels in a coming week. No long positions created and Short Nifty on every rally for now.
Our Previous Recommendation
If your friends and family joke that you're addicted to Facebook, they may be right. Researchers in Norway have identified six signs that you may be addicted. They've used those signs to develop a test to help you figure out of your suffer from a social media addiction.
![]() |
| Facebook Addiction |
• You spend a lot of time thinking about Facebook or plan use of Facebook.
• You feel an urge to use Facebook more and more.
• You use Facebook to forget about personal problems.
• You have tried to cut down on the use of Facebook without success.
• You become restless or troubled if you are prohibited from using Facebook.
• You use Facebook so much that it has had a negative impact on your job/studies.
If you are, indeed, addicted, you're not alone, the researchers say.
"The use of Facebook has increased rapidly. We are dealing with a subdivision of Internet addiction connected to social media," said Cecilie Schou Andreassen, who conducted the study.
Andreassen heads the research project "Facebook Addiction" at the University of Bergen (UiB) in Norway. The results of her research have just been published in the journal Psychological Reports.
Andreassen said she sees some clear patterns in Facebook addiction.
"It occurs more regularly among younger than older users. We have also found that people who are anxious and socially insecure use Facebook more than those with lower scores on those traits, probably because those who are anxious find it easier to communicate via social media than face-to-face," she said.
People who are organized and more ambitious tend to be less at risk from Facebook addiction. They will often use social media as an integral part of work and networking.
"Women are more at risk of developing Facebook addiction, probably due to the social nature of Facebook," Andreassen said.
Andreassen said the research also shows that Facebook addiction was related to extroversion. People with high scores on the new scale further tend to have a somewhat delayed sleep-wake rhythm.
The study was based on 423 students — 227 women and 196 men.
Despite Andreassen's findings, others are not as convinced about Internet-based addictions.
"There are often underlying or co-occurring psychiatric disorders, such as anxiety, depression or a disturbance in interpersonal relationships, all of which may explain the person's Internet problems,” Ronald W. Pies, a professor of clinical psychiatry at Tufts University told BusinessNewsDaily sister site LiveScience for a 2009 article. "The question is, do we need another 'disorder' in the APA's Diagnostic and Statistical Manual of Mental Disorders (DSM), if the manifestations of Internet addiction can already be accounted for by well-described and better-validated conditions?"
That, however, doesn’t mean that Pies is writing off the possibility of Internet-based addictions. Rather, he believes that better research is needed to quantify these behaviors.
"We may eventually come around to the view that Internet addiction is a discrete mental disorder, but that will require carefully designed research aimed at linking Internet addiction with family and genetic factors, biological concomitants and responses to specific treatments," Pies said.
Maintaining his high standards and living up to his own expectations still gives Sachin Tendulkar sleepless nights, and it is this restlessness that has brought the best out of him, revealed the Indian maestro in an interview published in the Timemagazine. Tendulkar is on the cover for the editions in the Indian subcontinent, Singapore and Australia and New Zealand.
| Sachin Tendulkar to appear on TIME magazine cover page |
StarTek, Inc today announced its financial results for the first quarter ended March 31, 2012. The Company reported first quarter 2012 revenue of $50.9 million and adjusted EBITDA of $1.2 million. As of March 31, 2012, the Company had approximately $10.5 million in cash and cash equivalents and no debt.
Highlights
* Garments, gems and jewellery exports shrink, hits growth
* Gold, jewellery imports plummet as demand slows
* Trade sec says "lucky" if 2012/13 exports grow 10-15 pct y/y
* Trade deficit may be slightly lower in 2012/13 - Trade sec (Adds quotes, details)
India's exports picked up in April after falling in March but only grew 3.2 percent from a year earlier and garment, gems and jewellery shipments shrank, highlighting the challenge facing Asia's third-biggest economy in the face of weak global demand.
India's foreign trade has slowed sharply from levels a year ago when exports jumped nearly 32 percent in April from a year earlier, and the country's trade secretary said on Thursday that the country would be "lucky" to achieve 10-15 percent export growth this fiscal year.
Imports were also surprisingly weak in April, rising just 3.8 percent from a year earlier, according to provisional data released on Thursday, reflecting weakening domestic demand and cooling after a 24.3 percent jump in March.
"We will be lucky if we can achieve 10-15 percent growth in exports this year," Rahul Khullar told a press conference. Exports rose 21 percent in 2011/12.
In March, exports fell for the first time in four months, dropping 5.7 percent year-on-year.
Besides a slowdown in exports, the economy is seeing a decline in capital inflows, which is putting pressure on the central bank to support the rupee - which has lost nearly 8 percent against the dollar since March.
On Thursday the Reserve Bank of India took further measures to prop up the battered currency, requiring exporters to sell half the foreign currency in their accounts.
Khullar said a falling rupee would affect imports in the next two to three months.
Analysts said amid a policy gridlock and global economic uncertainty, the central bank would find it tough to support the rupee.
GOLD IMPORTS PLUNGE
The country's trade deficit was $13.4 billion in April, Khullar said, as exports totalled $24.5 billion and imports amounted to $37.9 billion. The deficit was down slightly from $13.9 billion in March.
"It (the RBI) is battling a combination of an unsustainably large current account deficit of around 4 percent of GDP, weak/inadequate capital inflows and a government that is doing less of what it should do and more of what it should not do," said Rajeev Malik, a senior economist at CLSA in Singapore.
India's garment exports fell 20.4 percent in April from a year earlier, while gems and jewellery exports slumped 25.7 percent.
Imports of gold and silver declined by nearly a third to $3.1 billion in April, from $4.7 billion a year ago, as higher gold prices and an increase in import duties crimped local demand.
Oil imports grew 7 percent in April to $13.9 billion, while coal imports grew 5.5 percent to $1.5 billion from a year ago, Khullar said.
The trade deficit could narrow slightly in the current fiscal year which ends in March, from nearly $185 billion in 2011/12, assuming gold imports decline by at least 20 percent this year and there are no oil price shocks, Khullar said.
* Garments, gems and jewellery exports shrink, hits growth
* Gold, jewellery imports plummet as demand slows
* Trade sec says "lucky" if 2012/13 exports grow 10-15 pct y/y
* Trade deficit may be slightly lower in 2012/13 - Trade sec (Adds quotes, details)
India's exports picked up in April after falling in March but only grew 3.2 percent from a year earlier and garment, gems and jewellery shipments shrank, highlighting the challenge facing Asia's third-biggest economy in the face of weak global demand.
India's foreign trade has slowed sharply from levels a year ago when exports jumped nearly 32 percent in April from a year earlier, and the country's trade secretary said on Thursday that the country would be "lucky" to achieve 10-15 percent export growth this fiscal year.
Imports were also surprisingly weak in April, rising just 3.8 percent from a year earlier, according to provisional data released on Thursday, reflecting weakening domestic demand and cooling after a 24.3 percent jump in March.
"We will be lucky if we can achieve 10-15 percent growth in exports this year," Rahul Khullar told a press conference. Exports rose 21 percent in 2011/12.
In March, exports fell for the first time in four months, dropping 5.7 percent year-on-year.
Besides a slowdown in exports, the economy is seeing a decline in capital inflows, which is putting pressure on the central bank to support the rupee - which has lost nearly 8 percent against the dollar since March.
On Thursday the Reserve Bank of India took further measures to prop up the battered currency, requiring exporters to sell half the foreign currency in their accounts.
Khullar said a falling rupee would affect imports in the next two to three months.
Analysts said amid a policy gridlock and global economic uncertainty, the central bank would find it tough to support the rupee.
GOLD IMPORTS PLUNGE
The country's trade deficit was $13.4 billion in April, Khullar said, as exports totalled $24.5 billion and imports amounted to $37.9 billion. The deficit was down slightly from $13.9 billion in March.
"It (the RBI) is battling a combination of an unsustainably large current account deficit of around 4 percent of GDP, weak/inadequate capital inflows and a government that is doing less of what it should do and more of what it should not do," said Rajeev Malik, a senior economist at CLSA in Singapore.
India's garment exports fell 20.4 percent in April from a year earlier, while gems and jewellery exports slumped 25.7 percent.
Imports of gold and silver declined by nearly a third to $3.1 billion in April, from $4.7 billion a year ago, as higher gold prices and an increase in import duties crimped local demand.
Oil imports grew 7 percent in April to $13.9 billion, while coal imports grew 5.5 percent to $1.5 billion from a year ago, Khullar said.
The trade deficit could narrow slightly in the current fiscal year which ends in March, from nearly $185 billion in 2011/12, assuming gold imports decline by at least 20 percent this year and there are no oil price shocks, Khullar said.
![]() |
| Infospace Inc |
InfoSpace Inc ( NASDAQ: INSP ) jumped on quarterly earning report and guidance as both were above estimate. Company has acquired TaxACT tax preparation business.
Investment: Stock may be accumulated for investment purpose.
Bellevue, Wash.-based InfoSpace bought the web-based TaxACT business for $287.5 million in cash just before tax season, closing the deal on Jan. 31. Only months before then, TaxACT rival H&R Block Inc. (HRB) was blocked from acquiring the privately held company by the U.S. government over antitrust concerns.
Shares jumped 14% to $12.49 after hours, as InfoSpace beat its first-quarter revenue guidance and reached the high end of its earnings estimates. The stock, which rose initially over the TaxACT acquisition, had slid since mid-March and was roughly flat for the year at Wednesday's close.
"The acquisition of TaxACT in January represents a significant milestone for our company, and substantially diversifies our overall business operations," Chief Executive Bill Ruckelshaus said. "We are pleased with the performance in both our search and tax preparation businesses and feel positive about our combined company growth and profitability outlook."
InfoSpace posted earnings of $11.4 million, or 28 cents a share, up from $1.3 million, or 4 cents a share, a year earlier. Revenue more than doubled to $115.7 million.
The company in February predicted earnings of 24 cents to 29 cents a share on revenue of $109 million to $114 million.
Search revenue in the quarter improved 46% to $75.3 million, while tax preparation revenue from TaxACT was $40.4 million. The company also released preliminary 2011 tax season figures, saying digital do-it-yourself e-filings rose 8% from the year-ago period to 5 million as of April 18.
Gross margin rose to 48.5% from 36.7%.
The company forecast second-quarter adjusted earnings of 40 cents to 44 cents a share on revenue of $92.5 million to $96.5 million
Stock Markets are on artificial life line of "QE3 hope" and if markets continue to move higher and makes new high, without QE3 in second half will lead to a crash like 1987 according to comments from Mark Faber. Read Below
U.S. stocks may plunge in the second half of the year “like in 1987” if the Standard & Poor’s 500 Index climbs without further stimulus from the Federal Reserve, said Marc Faber, the publisher of the Gloom, Boom & Doom report.
“I think the market will have difficulties to move up strongly unless we have a massive QE3,” Faber told Betty Liu on Bloomberg Television’s “In the Loop” from Zurich today, referring to a third round of large-scale asset purchases by the Federal Reserve. “If it moves and makes a high above 1,422, the second half of the year could witness a crash, like in 1987.”
May 10 (Bloomberg) -- Marc Faber, publisher of the Gloom, Boom & Doom report, talks about U.S. stocks and economy. Faber, speaking with Betty Liu on Bloomberg Television's "In the Loop," also discusses his view on the euro and the euro zone. (Source: Bloomberg)
The Dow Jones Industrial Average plunged 23 percent on Oct. 19, 1987 in the biggest crash since 1914, triggering sharp losses in stock-market values around the world. The Standard & Poor’s 500 Index (SPX) plummeted 20 percent.
“If the market makes a new high, it will be a new high with very few stocks pushing up and the majority of stocks having already rolled over,” Faber said. “The earnings outlook is not particularly good because most economies in the world are slowing down.”
Faber said a third round of quantitative easing would “definitely occur” if the S&P 500 dropped another 100 to 150 points. If it bounces back to 1,400, he said, the Fed will probably wait to see how the economy develops.
The S&P 500 rose 0.4 percent to 1,360.59 at 10:36 a.m. in New York as U.S. initial jobless claims fell last week to a one- month low. The gauge has dropped 4.1 percent from a four-year high on April 2 after some economic reports missed forecasts.
Equity Gains
Faber had said in an interview with Bloomberg Television on March 9, 2009, that it was “very difficult to see a scenario where you wouldn’t make any money” owning stocks over the following 10 years, while also warning the S&P 500 might lose 26 percent before the bear market ended.
The benchmark gauge for American equities began its biggest advance in five decades that day, climbing from 676.53 to 1,295.02 on Jan. 18, 2011.
In March 2007, he had said the S&P 500 was more likely to fall than rise because the threats of faster inflation and slower growth persisted. The S&P 500 then climbed 10 percent to a record 1,565.15 seven months later, and ended the year up 3.5 percent.




